A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults - Adaptive COVID-19 Treatment Trial (ACTT)

Regents of the University of Minnesota0 个研究点目标入组 1,032 人开始时间: 2020年4月2日最近更新: 2020年6月29日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Regents of the University of Minnesota
入组人数: 1,032

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•ACTT Stage 2:
•1. Admitted to a hospital with symptoms suggestive of COVID-19.
•2. Subject (or legally authorised representative) provides informed consent prior to initiation of any study procedures.
•3. Subject (or legally authorised representative) understands and agrees to comply with planned study procedures.
•4. Male or non-pregnant female adults = 18 years of age at time of enrolment.
•5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assayin any specimen, as documented by either of the following:PCR positive in sample collected < 72 hours prior to randomisation; ORPCR positive in sample collected = 72 hours prior to randomisation, documented inability to obtain a repeat sample(e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc) AND progressive diseasesuggestive of ongoing SARS-CoV-2 infection.
•6. Illness of any duration, and at least one of the following:
•Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), ORSpO2 = 94% on room air, OR
•Requiring supplemental oxygen, ORRequiring mechanical ventilation or ECMO.
•7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception
•not including hormonal contraception from the time of screening through Day 29.
•8. Agrees to not participate in another clinical trial for the treatment of COVID-19 through Day 29.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 33
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 33

排除标准

•ACTT Stage 2:
•1. ALT or AST > 5 times the upper limit of normal.
•2. Estimated glomerular filtration rate (eGFR) < 30 ml/min or patient is receiving hemodialysis or hemofiltration at timeof screening.
•3. Neutropenia (absolute neutrophil count <1000 cells/µL) (<1.0 x 103/µL or <1.0 GI/L).
•4. Lymphopenia (absolute lymphocyte count <200 cells/µL) (<0.20 x 103/µL or <0.20 GI/L)
•5. Pregnancy or breast feeding.
•6. Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.
•7. Allergy to any study medication.
•8. Received three or more doses of remdesivir including the loading dose, outside of the study under the EUA (or
•similar mechanism) for COVID-19.
•9. Received convalescent plasma or intravenous immunoglobulin (IVIg) for COVID-19, the current illness for whichthey are being enrolled.
•10. Received small molecule tyrosine kinase inhibitors (e.g., baricitinib, imatibib, genfinitib) in the 1 week prior to
•11. Received monoclonal antibodies targeting cytokines (e.g., TNF inhibitors, anti-interleukin-1 [IL-1], anti-IL-6
•[tocilizumab or sarilumab]) or cells (e.g., abatacept) in the 4 weeks prior to screening.
•12. Received monoclonal antibodies targeting B-cell (e.g., rituximab, and including any targeting multiple cell lines
•including B-cells) in the 3 months prior to screening.
•13. Received other immunosuppressants in the 4 weeks prior to screening and in the judgement of the investigator,
•the risk of immunosuppression with baricitinib is larger than the risk of COVID-19.
•14. Received =20 mg/day of prednisone or equivalent for =14 consecutive days in the 4 weeks prior to screening.
•15. Use of probenecid that cannot be discontinued at study enrollment.
•16. Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with
•appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening required).
•17. Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the
•investigator could constitute a risk when taking investigational product.
•18. Have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a livevaccine (or live attenuated) during the study. Note: Use of non-live (inactivated) vaccinations is allowed for all subjects.
•19. Have a history of VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 12 weeks prior to
•screening or have a history of recurrent (>1) VTE (DVT/PE).
•20. Immunocompromised patients, patients with a chronic medical condition, or those taking a medication that cannot be discontinued at enrollment, who, in the judgment of PI, are at increased risk for serious infections or other safety concerns given the study products.

研究者

发起方

Regents of the University of Minnesota

相似试验

进行中（未招募）

1 期

A Multicentre, Adaptive, Randomised, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalised Adults

EUCTR2020-001052-18-GBRegents of the University of Minnesota440

进行中（未招募）

1 期

A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for Eurpean Union/United Kingdom SitesAdaptive COVID-19 Treatment Trial in the EU & UK (ACTT/EU/UKInfluenza COVID-19MedDRA version: 20.0Level: HLTClassification code 10022005Term: Influenza viral infectionsSystem Organ Class: 100000004862

EUCTR2020-001052-18-DKRegents of the University of Minnesota800

进行中（未招募）

1 期

EUCTR2020-001052-18-DERegents of the University of Minnesota800

进行中（未招募）

1 期

EUCTR2020-001052-18-ESRegents of the University of Minnesota1,062

进行中（未招募）

1 期

Therapeutics for Inpatients with COVID-19 (TICO)

EUCTR2020-003278-37-PLRegents of the University of Minesota1,000